title: Cancer immunotherapy in veterinary medicine: Current options and new developments.
abstract: Excitement in the field of tumor immunotherapy is being driven by several remarkable breakthroughs in recent years. This review will cover recent advances in cancer immunotherapy, including the use of T cell checkpoint inhibitors, engineered T cells, cancer vaccines, and anti-B cell and T cell antibodies. Inhibition of T cell checkpoint molecules such as PD-1 and CTLA-4 using monoclonal antibodies has achieved notable success against advanced tumors in humans, including melanoma, renal cell carcinoma, and non-small cell lung cancer. Therapy with engineered T cells has also demonstrated remarkable tumor control and regression in human trials. Autologous cancer vaccines have recently demonstrated impressive prolongation of disease-free intervals and survival times in dogs with lymphoma. In addition, caninized monoclonal antibodies targeting CD20 and CD52 just recently received either full (CD20) or conditional (CD52) licensing by the United States Department of Agriculture for clinical use in the treatment of canine B-cell and T-cell lymphomas, respectively. Thus, immunotherapy for cancer is rapidly moving to the forefront of cancer treatment options in veterinary medicine as well as human medicine.
authors.affiliation: Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Regan
authors.affiliation: Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA.
authors.forename: Amanda
authors.initials: A
authors.lastname: Guth
authors.affiliation: Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Coy
authors.affiliation: Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523, USA. Electronic address: sdow@colostate.edu.
authors.forename: Steven
authors.initials: S
authors.lastname: Dow
mesh_terms: D000818:Animals; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy / Q000662:veterinary*; D014730:Veterinary Medicine / Q000639:trends*
keywords: Antibody; Cancer; Dog; Immune system; Macrophage; T cell; Treatment